All patients
Age < 65y (younger) Age > 65y cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), pembrolizumab plus ipilimumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-598, 2020 1.08 [0.85; 1.37]
1.08 [0.85 ; 1.37 ] KEYNOTE-598, 2020 1 0% 568 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-598, 2020 1.06 [0.86; 1.30]
1.06 [0.86 ; 1.30 ] KEYNOTE-598, 2020 1 0% 568 NA not evaluable objective responses (ORR)detailed results KEYNOTE-598, 2020 1.00 [0.72; 1.39]
1.00 [0.72 ; 1.39 ] KEYNOTE-598, 2020 1 0% 568 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.14 [0.41; 3.20]
1.14 [0.41 ; 3.20 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.01 [0.36; 11.05]
2.01 [0.36 ; 11.05 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.25 [0.03; 2.22]
0.25 [0.03 ; 2.22 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.04; 5.51]
0.50 [0.04 ; 5.51 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.00 [0.14; 7.12]
1.00 [0.14 ; 7.12 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-598, 2020 6.03 [0.30; 120.98]
6.03 [0.30 ; 120.98 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-598, 2020 10.29 [1.31; 80.96]
10.29 [1.31 ; 80.96 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.87 [0.31; 2.43]
0.87 [0.31 ; 2.43 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.51 [0.42; 5.39]
1.51 [0.42 ; 5.39 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.00 [0.06; 16.01]
1.00 [0.06 ; 16.01 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.52 [0.48; 13.09]
2.52 [0.48 ; 13.09 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.28 [0.69; 7.50]
2.28 [0.69 ; 7.50 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-598, 2020 4.01 [0.18; 89.26]
4.01 [0.18 ; 89.26 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pneumonia AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.36 [0.72; 2.56]
1.36 [0.72 ; 2.56 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.21 [0.83; 5.91]
2.21 [0.83 ; 5.91 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.04; 5.51]
0.50 [0.04 ; 5.51 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-598, 2020 6.03 [0.30; 120.98]
6.03 [0.30 ; 120.98 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-598, 2020 16.38 [0.94; 286.59]
16.38 [0.94 ; 286.59 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-598, 2020 4.03 [0.45; 36.27]
4.03 [0.45 ; 36.27 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:40 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 769